Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?

Quarterly Reviews of Biophysics

Volumn 39, Issue 2, 2006, Pages 167-201

  Lashuel, Hilal A ^a   Lansbury Jr , Peter T ^b,c  

^a EPFL   (Switzerland)

^b Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; AMYLOID BETA PROTEIN; BACTERIAL TOXIN; HUNTINGTIN; ION CHANNEL; POLYGLUTAMINE; PRION PROTEIN; SUPEROXIDE DISMUTASE; VIRULENCE FACTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BOVINE SPONGIFORM ENCEPHALOPATHY; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; HUMAN; HUNTINGTON CHOREA; MEMBRANE TRANSPORT; MOLECULAR MIMICRY; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN DEGRADATION; REVIEW;

AGING; ALZHEIMER DISEASE; AMYLOID; CELL DEATH; HUMANS; LEWY BODY DISEASE; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX;

BACTERIA (MICROORGANISMS);

EID: 33750365052     PISSN: 00335835     EISSN: 14698994     Source Type: Journal    
DOI: 10.1017/S0033583506004422     Document Type: Review

References (308)

1. ABOU-SLEIMAN, P. M., MUQIT, M. M. & WOOD, N. W. (2006). Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nature Reviews Neuroscience 7, 207-219.
2. ABRAMI, L., FIVAZ, M., DECROLY, E., SEIDAH, N. G., JEAN, F., THOMAS, G., LEPPLA, S. H., BUCKLEY, J. T. & VAN DER GOOT, F. G. (1998). The pore-forming toxin proaerolysin is activated by furin. Journal of Biological Chemistry 273, 32656-32661.
3. AKSENOVA, M. V., AKSENOV, M. Y., BUTTERFIELD, D. A. & CARNEY, J. M. (1996). alpha-1-antichymotrypsin interaction with A beta (1-40) inhibits fibril formation but does not affect the peptide toxicity. Neuroscience Letters 211, 45-48.
4. ALARCON, J. M., BRITO, J. A., HERMOSILLA, T., ATWATER, I., MEARS, D. & ROJAS, E. (2006). Ion channel formation by Alzheimer's disease amyloid beta-peptide (Abeta40) in unilamellar liposomes is determined by anionic phospholipids. Peptides 27, 95-104.
5. ANGUIANO, M., NOWAK, R. J. & LANSBURY JR., P. T. (2002). Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41, 11338-11343.
6. ARISPE, N. & DOH, M. (2002). Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) Peptides. Faseb Journal 16, 1526-1536.
7. ARISPE, N., POLLARD, H. B. & ROJAS, E. (1993a). Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proceedings of the National Academy of Sciences USA 90, 10573-10577.
8. 2+)-channel hypothesis for neuronal death in Alzheimer disease. Molecular and Cellular Biochemistry 140, 119-125.
9. 2+ interaction with Alzheimer amyloid beta protein calcium channels. Proceedings of the National Academy of Sciences USA 93, 1710-1715.
10. ARISPE, N., ROJAS, E. & POLLARD, H. B. (1993b). Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proceedings of the National Academy of Sciences USA 90, 567-571.
11. AZIMOV, R., AZIMOVA, R., HIRAKURA, Y. & KAGAN, B. L. (2001). Ion channels of different selectivity formed by transthyretin. Biophysical Journal 80, 129a.
12. 2+-induced modification of the kinetics of Aβ[[LB]]1-42[[RB]] channels. American Journal of Physiology - Cell Physiology 285, C873-C880.
13. BAHADI, R., FARRELLY, P. V., KENNA, B. L., KOURIE, J. I., TAGLIAVINI, F., FORLONI, G. & SALMONA, M. (2003b). Channels formed with a mutant prion protein PrP (82-146) homologous to a 7-kDa fragment in diseased brain of GSS patients. American Journal of Physiology - Cell Physiology 285, C862-872.
14. BAHADI, R., FARRELLY, P. V., KENNA, B. L., KOURIE, J. I., TAGLIAVINI, F., FORLONI, G. & SALMONA, M. (2003c). Ion channels formed with a synthetic mutant prion protein (PrP[[LB]]82-146[[RB]]) homologous to a 7 kDa fragment found in the diseased brain of Gerstmann-Straussler-Scheinker syndrome. American Journal of Physiology - Cell Physiology 285, C862-C872.
15. BARGHORN, S., NIMMRICH, V., STRIEBINGER, A., KRANTZ, C., KELLER, P., JANSON, B., BAHR, M., SCHMIDT, M., BITNER, R. S., HARLAN, J., BARLOW, E., EBERT, U. & HILLEN, H. (2005). Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. Journal of Neurochemistry 95, 834-847.
16. BARRACHINA, M., CASTANO, E., DALFO, E., MAES, T., BUESA, C. & FERRER, I. (2005). Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies. Neurobiology of Disease Journal 22, 265-273.
17. BASKAKOV, I. V., AAGAARD, C., MEHLHORN, I., WILLE, H., GROTH, D., BALDWIN, M. A., PRUSINER, S. B. & COHEN, F. E. (2000). Self-assembly of recombinant prion protein of 106 residues. Biochemistry 39, 2792-2804.
18. BASKAKOV, I. V., LEGNAME, G., BALDWIN, M. A., PRUSINER, S. B. & COHEN, F. E. (2002). Pathway complexity of prion protein assembly into amyloid. Journal of Biological Chemistry 277, 21140-21148.
19. BEHRENS, A. & AGUZZI, A. (2002). Small is not beautiful: antagonizing functions for the prion protein PrP(C) and its homologue Dpl. Trends in Neurosciences 25, 150-154.
20. BEN-ZVI, A., DE LOS RIOS, P., DIETLER, G. & GOLOUBINOFF, P. (2004). Active solubilization and refolding of stable protein aggregates by cooperative unfolding action of individual hsp70 chaperones. Journal of Biological Chemistry 279, 37298-37303.
21. BEN-ZVI, A. P. & GOLOUBINOFF, P. (2001). Review: mechanisms of disaggregation and refolding of stable protein aggregates by molecular chaperones. Journal of Structural Biology 135, 84-93.
22. BENNETT, E. J., BENCE, N. F., JAYAKUMAR, R. & KOPITO, R. R. (2005). Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Molecular Cell 17, 351-365.
23. BERKE, S. J. & PAULSON, H. L. (2003). Protein aggregation and the ubiquitin proteasome pathway: gaining the upper hand on neurodegeneration. Current Opinion in Genetics & Development 13, 253-261.
24. BHATIA, R., LIN, H. & LAL, R. (2000). Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. FASEB Journal 14, 1233-1243.
25. BROWN JR., R. H. (1997). Amyotrophic lateral sclerosis. Insights from genetics. Archives of Neurology 54, 1246-1250.
26. BRUIJN, L. I., HOUSEWEART, M. K., KATO, S., ANDERSON, K. L., ANDERSON, S. D., OHAMA, E., REAUME, A. G., SCOTT, R.W. & CLEVELAND, D. W. (1998). Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851-1854.
27. BUCCIANTINI, M., GIANNONI, E., CHITI, F., BARONI, F., FORMIGLI, L., ZURDO, J., TADDEI, N., RAMPONI, G., DOBSON, C.M. & STEFANI, M. (2002). Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511.
28. BUTLER, A. E., JANSON, J., SOELLER, W. C. & BUTLER, P. C. (2003). Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52, 2304-2314.
29. CABIAUX, V., WOLFF, C. & RUYSSCHAERT, J. M. (1997). Interaction with a lipid membrane: a key step in bacterial toxins virulence. International Journal of Biological Macromolecules 21, 285-298.
30. CAPPAI, R., LECK, S. L., TEW, D. J., WILLIAMSON, N. A., SMITH, D. P., GALATIS, D., SHARPLES, R. A., CURTAIN, C. C., ALI, F. E., CHERNY, R. A., CULVENOR, J. G., BOTTOMLEY, S. P., MASTERS, C. L., BARNHAM, K. J. & HILL, A. F. (2005). Dopamine promotes alphasynuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB Journal 19, 1377-1379.
31. CARDOSO, I., GOLDSBURY, C. S., MULLER, S. A., OLIVIERI, V., WIRTZ, S., DAMAS, A. M., AEBI, U. & SARAIVA, M. J. (2002a). Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils. Journal of Molecular Biology 317, 683-695.
32. CARDOSO, R. M., THAYER, M. M., DIDONATO, M., LO, T. P., BRUNS, C. K., GETZOFF, E. D. & TAINER, J. A. (2002b). Insights into Lou Gehrig's disease from the structure and instability of the A4V mutant of human Cu,Zn superoxide dismutase. Journal of Molecular Biology 324, 247-256.
33. CAUGHEY, B. & LANSBURY, P. T. (2003). Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annual Review of Neuroscience 26, 267-298.
34. CHEN, L. & FEANY, M. B. (2005). Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nature Neuroscience 8, 657-663.
35. CHIESA, R. & HARRIS, D. A. (2001). Prion diseases: what is the neurotoxic molecule? Neurobiology of Disease Journal 8, 743-763.
36. CHIESA, R., PICCARDO, P., QUAGLIO, E., DRISALDI, B., SIHOE, S. L., TAKAO, M., GHETTI, B. & HARRIS, D.A. (2003). Molecular distinction between pathogenic and infectious properties of the prion protein. Journal of Virology 77, 7611-7622.
37. CHROMY, B. A., NOWAK, R. J., LAMBERT, M. P., VIOLA, K. L., CHANG, L., VELASCO, P. T., JONES, B. W., FERNANDEZ, S. J., LACOR, P. N., HOROWITZ, P., FINCH, C. E., KRAFFT, G. A. & KLEIN, W. L. (2003). Self-assembly of Abeta (1-42) into globular neurotoxins. Biochemistry 42, 12749-12760.
38. CHUI, D. H., TANAHASHI, H., OZAWA, K., IKEDA, S., CHECLER, F., UEDA, O., SUZUKI, H., ARAKI, W., INOUE, H., SHIROTANI, K., TAKAHASHI, K., GALLYAS, F. & TABIRA, T. (1999). Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nature Medicine 5, 560-564.
39. CHUNG, J., YANG, H., DE BEUS, M. D., RYU, C. Y., CHO, K, COLON, W. (2003). Cu/Zn superoxide dismutase can form pore-like structures. Biochemical and Biophysical Research Communications 312, 873-876.
40. CLEARY, J. P., WALSH, D. M., HOFMEISTER, J. J., SHANKAR, G. M., KUSKOWSKI, M. A., SELKOE, D. J. & ASHE, K. H. (2005). Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nature Neuroscience 8, 79-84.
41. COHEN, F. E. & PRUSINER, S. B. (1998). Pathologic conformations of prion proteins. Annual Review of Biochemistry 67, 793-819.
42. CONWAY, K. A., HARPER, J. D. & LANSBURY, P. T. (1998). Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nature Medicine 4, 1318-1320.
43. CONWAY, K. A., LEE, S. J., ROCHET, J. C., DING, T. T., WILLIAMSON, R. E. & LANSBURY JR., P. T. (2000). Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proceedings of the National Academy of Sciences USA 97, 571-576.
44. CONWAY, K. A., ROCHET, J. C., BIEGANSKI, R. M. & LANSBURY JR., P. T. (2001). Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346-1349.
45. COOKSON, M. R. (2005). The biochemistry of Parkinson's disease. Annual Review of Biochemistry 74, 29-52.
46. CRYSTAL, A. S., GIASSON, B. I., CROWE, A., KUNG, M. P., ZHUANG, Z. P., TROJANOWSKI, J. Q. & LEE, V. M. (2003). A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. Journal of Neurochemistry 86, 1359-1368.
47. CURTAIN, C. C., ALI, F. E., SMITH, D. G., BUSH, A. I., MASTERS, C. L. & BARNHAM, K. J. (2003). Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. Journal of Biological Chemistry 278, 2977-2982.
48. DAHLGREN, K. N., MANELLI, A. M., STINE JR., W. B., BAKER, L. K., KRAFFT, G. A. & LADU, M. J. (2002). Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. Journal of Biological Chemistry 277, 32046-32053.
49. DAUER, W. & PRZEDBORSKI, S. (2003). Parkinson's disease: mechanisms and models. Neuron 39, 889-909.
50. DE KONING, E. J., HOPPENER, J. W., VERBEEK, J. S., OOSTERWIJK, C., VAN HULST, K. L., BAKER, C. A., LIPS, C. J., MORRIS, J.F. & CLARK, A. (1994). Human islet amyloid polypeptide accumulates at similar sites in islets of transgenic mice and humans. Diabetes 43, 640-644.
51. DEMURO, A., MINA, E., KAYED, R., MILTON, S. C., PARKER, I. & GLABE, C. G. (2005). Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. Journal of Biological Chemistry 280, 17294-17300.
52. DING, T. T., LEE, S. J., ROCHET, J. C. & LANSBURY JR., P. T. (2002). Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41, 10209-10217.
53. DOBSON, C. M. (2001). The structural basis of protein folding and its links with human disease. Philosophical Transactions of the Royal Society B: Biological Sciences 356, 133-145.
54. DZWOLAK, W., GRUDZIELANEK, S., SMIRNOVAS, V., RAVINDRA, R., NICOLINI, C., JANSEN, R., LOKSZTEJN, A., POROWSKI, S. & WINTER, R. (2005). Ethanol-perturbed amyloidogenic self-assembly of insulin: looking for origins of amyloid strains. Biochemistry 44, 8948-8958.
55. ECKERT, G. P., KIRSCH, C., LEUTZ, S., WOOD, W. G. & MULLER, W. E. (2003). Cholesterol modulates amyloid beta-peptide's membrane interactions. Pharmacopsychiatry 36 (Suppl. 2), S136-S143.
56. EL-AGNAF, O. M., JAKES, R., CURRAN, M.D. & WALLACE, A. (1998). Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Letters 440, 67-70.
57. EL-AGNAF, O. M., MAHIL, D. S., PATEL, B. P. & AUSTEN, B. M. (2000). Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. Biochemical and Biophysical Research Communications 273, 1003-1007.
58. EL-AGNAF, O. M., NAGALA, S., PATEL, B. P. & AUSTEN, B. M. (2001a). Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. Journal of Molecular Biology 310, 157-168.
59. EL-AGNAF, O. M., SALEM, S. A., PALEOLOGOU, K. E., CURRAN, M. D., GIBSON, M. J., COURT, J. A., SCHLOSSMACHER, M. G. & ALLSOP, D. (2006). Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB Journal 20, 419-425.
60. EL-AGNAF, O. M., SHERIDAN, J. M., SIDERA, C., SILIGARDI, G., HUSSAIN, R., HARIS, P. I. & AUSTEN, B. M. (2001b). Effect of the disulfide bridge and the C-terminal extension on the oligomerization of the amyloid peptide ABri implicated in familial British dementia. Biochemistry 40, 3449-3457.
61. ELAM, J. S., TAYLOR, A. B., STRANGE, R., ANTONYUK, S., DOUCETTE, P. A., RODRIGUEZ, J. A., HASNAIN, S. S., HAYWARD, L. J., VALENTINE, J. S., YEATES, T.O. & HART, P. J. (2003). Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS. Nature Structural Biology 10, 461-467.
62. FALSEY, A. R., WALSH, E. E., FRANCIS, C. W., LOONEY, R. J., KOLASSA, J. E., HALL, W. J. & ABRAHAM, G.N. (2001). Response of C-reactive protein and serum amyloid A to influenza A infection in older adults. Journal of Infectious Diseases 183, 995-999.
63. FEANY, M. B. & BENDER, W. W. (2000). A Drosophila model of Parkinson's disease. Nature 404, 394-398.
64. FERRINGTON, D. A., HUSOM, A. D. & THOMPSON, L. V. (2005). Altered proteasome structure, function, and oxidation in aged muscle. FASEB Journal 19, 644-646.
65. FLYNN, B. L. & THEESEN, K. A. (1999). Pharmacologic management of Alzheimer disease part III: nonsteroidal antiinflammatory drugs - emerging protective evidence? Annals of Pharmacotherapy 33, 840-849.
66. FUJIWARA, H., HASEGAWA, M., DOHMAE, N., KAWASHIMA, A., MASLIAH, E., GOLDBERG, M. S., SHEN, J., TAKIO, K. & IWATSUBO, T. (2002). alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biology 4, 160-164.
67. FUNATO, H., ENYA, M., YOSHIMURA, M., MORISHIMA-KAWASHIMA, M. & IHARA, Y. (1999). Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. American Journal of Pathology 155, 23-28.
68. FUSSLE, R., BHAKDI, S., SZIEGOLEIT, A., TRANUM-JENSEN, J., KRANZ, T. & WELLENSIEK, H. J. (1981). On the mechanism of membrane damage by Staphylococcus aureus alpha-toxin. Journal of Cell Biology 91, 83-94.
69. GACZYNSKA, M., OSMULSKI, P.A. & WARD, W. F. (2001). Caretaker or undertaker? The role of the proteasome in aging. Mechanisms of Ageing and Development 122, 235-254.
70. GAMBETTI, P., PARCHI, P., PETERSEN, R. B., CHEN, S. G. & LUGARESI, E. (1995). Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical, pathological and molecular features. Brain Pathology 5, 43-51.
71. GHISO, J., VIDAL, R., ROSTAGNO, A., MIRAVALLE, L., HOLTON, J. L., MEAD, S., REVESZ, T., PLANT, G. & FRANGIONE, B. (2000). Amyloidogenesis in familial British dementia is associated with a genetic defect on chromosome 13. Annals of the New York Academy of Sciences 920, 84-92.
72. GIASSON, B. I. & LEE, V. M. (2003). Are ubiquitination pathways central to Parkinson's disease? Cell 114, 1-8.
73. GLENNER, G.G. & WONG, C. W. (1984). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and Biophysical Research Communications 120, 885-890.
74. GOLDBERG, M. S. & LANSBURY JR., P. T. (2000). Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nature Cell Biology 2, E115-E119.
75. GOLDSBURY, C., FREY, P., OLIVIERI, V., AEBI, U. & MULLER, S. A. (2005). Multiple assembly pathways underlie amyloid-beta fibril polymorphisms. Journal of Molecular Biology 352, 282-298.
76. GONG, Y., CHANG, L., VIOLA, K. L., LACOR, P. N., LAMBERT, M. P., FINCH, C. E., KRAFFT, G. A. & KLEIN, W. L. (2003). Alzheimer's disease-affected brain: presence of oligomeric A{beta} ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences USA 100, 10417-10422.
77. GOSAVI, N., LEE, H. J., LEE, J. S., PATEL, S. & LEE, S. J. (2002). Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. Journal of Biological Chemistry 277, 48984-48992.
78. GREEN, J., GOLDSBURY, C., MINI, T., SUNDERJI, S., FREY, P., KISTLER, J., COOPER, G. & AEBI, U. (2003). Full-length rat amylin forms fibrils following substitution of single residues from human amylin. Journal of Molecular Biology 326, 1147-1156.
79. GREEN, J. D., GOLDSBURY, C., KISTLER, J., COOPER, G. S. & AEBI, U. (2004). Human amylin oligomer growth and fibril elongation define two distinct phases in amyloid formation. Journal of Biological Chemistry 279, 12206-12212.
80. HAFNER, J. H., CHEUNG, C. L., WOOLLEY, A. T. & LIEBER, C. M. (2001). Structural and functional imaging with carbon nanotube AFM probes. Progress in Biophysics & Molecular Biology 77, 73-110.
81. HARDY, J. & SELKOE, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
82. HARDY, J. A. & HIGGINS, G. A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
83. HARPER, J. D., LIEBER, C. M. & LANSBURY JR., P. T. (1997a). Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chemistry & Biology 4, 951-959.
84. HARPER, J. D., WONG, S. S., LIEBER, C. M. & LANSBURY, P. T. (1997b). Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chemistry & Biology 4, 119-125.
85. HARPER, J. D., WONG, S. S., LIEBER, C. M. & LANSBURY JR., P. T. (1999). Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 38, 8972-8980.
86. HARRIS, D. A., CHIESA, R., DRISALDI, B., QUAGLIO, E., MIGHELI, A., PICCARDO, P. & GHETTI, B. (2003). A murine model of a familial prion disease. Clinical Laboratory Medicine 23, 175-186.
87. HARROUN, T. A., BRADSHAW, J. P. & ASHLEY, R. H. (2001). Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation. FEBS Letters 507, 200-204.
88. HARTLEY, D. M., WALSH, D. M., YE, C. P., DIEHL, T., VASQUEZ, S., VASSILEV, P. M., TEPLOW, D. B. & SELKOE, D. J. (1999). Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. Journal of Neuroscience 19, 8876-8884.
89. HASHIMOTO, M., ROCKENSTEIN, E., MANTE, M., MALLORY, M. & MASLIAH, E. (2001). beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an antiparkinsonian factor. Neuron 32, 213-223.
90. HAYWARD, L. J., RODRIGUEZ, J. A., KIM, J. W., TIWARI, A., GOTO, J. J., CABELLI, D. E., VALENTINE, J. S. & BROWN JR., R. H. (2002). Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis. Journal of Biological Chemistry 277, 15923-15931.
91. HEGDE, R. S., TREMBLAY, P., GROTH, D., DEARMOND, S. J., PRUSINER, S. B. & LINGAPPA, V. R. (1999). Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 402, 822-826.
92. HELMS, L. R. & WETZEL, R. (1996). Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis. Journal of Molecular Biology 257, 77-86.
93. HEUCK, A. P., TWETEN, R. K. & JOHNSON, A. E. (2001). Beta-barrel pore-forming toxins: intriguing dimorphic proteins. Biochemistry 40, 9065-9073.
94. HEUCK, A. P., TWETEN, R. K. & JOHNSON, A. E. (2003). Assembly and topography of the prepore complex in cholesterol-dependent cytolysins. Journal of Biological Chemistry 278, 31218-31225.
95. HEYDARI, A. R., CONRAD, C. C. & RICHARDSON, A. (1995). Expression of heat shock genes in hepatocytes is affected by age and food restriction in rats. Journal of Nutrition 125, 410-418.
96. HIRAKURA, Y., AZIMOV, R., AZIMOVA, R. & KAGAN, B. L. (2000a). Polyglutamine-induced ion channels: a possible mechanism for the neurotoxicity of Huntington and other CAG repeat diseases. Journal of Neuroscience Research 60, 490-494.
97. HIRAKURA, Y., CARRERAS, I., SIPE, J. D. & KAGAN, B. L. (2002). Channel formation by serum amyloid A: a potential mechanism for amyloid pathogenesis and host defense. Amyloid 9, 13-23.
98. HIRAKURA, Y. & KAGAN, B. L. (2001). Pore formation by beta-2-microglobulin: a mechanism for the pathogenesis of dialysis associated amyloidosis. Amyloid 8, 94-100.
99. HIRAKURA, Y., LIN, M. C. & KAGAN, B. L. (1999). Alzheimer amyloid abeta 1-42 channels: effects of solvent, pH, and Congo Red. Journal of Neuroscience Research 57, 458-466.
100. HIRAKURA, Y., YIU, W. W., YAMAMOTO, A. & KAGAN, B. L. (2000b). Amyloid peptide channels: blockade by zinc and inhibition by Congo red (amyloid channel block). Amyloid 7, 194-199.
101. HIRSCH, E. C., FAUCHEUX, B., DAMIER, P., MOUATT-PRIGENT, A. & AGID, Y. (1997). Neuronal vulnerability in Parkinson's disease. Journal of Neural Transmission 50 (Suppl.), 79-88.
102. HOLTON, J. L., GHISO, J., LASHLEY, T., ROSTAGNO, A., GUERIN, C. J., GIBB, G., HOULDEN, H., AYLING, H., MARTINIAN, L., ANDERTON, B. H., WOOD, N. W., VIDAL, R., PLANT, G., FRANGIONE, B. & REVESZ, T. (2001). Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia. American Journal of Pathology 158, 515-526.
103. HOSHI, M., SATO, M., MATSUMOTO, S., NOGUCHI, A., YASUTAKE, K., YOSHIDA, N. & SATO, K. (2003). Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proceedings of the National Academy of Sciences USA 100, 6370-6375.
104. HOTZE, E. M., WILSON-KUBALEK, E. M., ROSSJOHN, J., PARKER, M. W., JOHNSON, A. E. & TWETEN, R.K. (2001). Arresting pore formation of a cholesterol-dependent cytolysin by disulfide trapping synchronizes the insertion of the transmembrane beta-sheet from a prepore intermediate. Journal of Biological Chemistry 276, 8261-8268.
105. HSIA, A. Y., MASLIAH, E., MCCONLOGUE, L., YU, G. Q., TATSUNO, G., HU, K., KHOLODENKO, D., MALENKA, R. C., NICOLL, R. A. & MUCKE, L. (1999). Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proceedings of the National Academy of Sciences USA 96, 3228-3233.
106. HUANG, T. H., YANG, D. S., PLASKOS, N. P., GO, S., YIP, C. M., FRASER, P. E. & CHAKRABARTTY, A. (2000). Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. Journal of Molecular Biology 297, 73-87.
107. ISHIMARU, D., ANDRADE, L. R., TEIXEIRA, L. S., QUESADO, P. A., MAIOLINO, L. M., LOPEZ, P. M., CORDEIRO, Y., COSTA, L. T., HECKL, W. M., WEISSMULLER, G., FOGUEL, D. & SILVA, J. L. (2003). Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry 42, 9022-9027.
108. JANSON, J., ASHLEY, R. H., HARRISON, D., MCINTYRE, S. & BUTLER, P. C. (1999). The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48, 491-498.
109. JANSON, J., SOELLER, W. C., ROCHE, P. C., NELSON, R. T., TORCHIA, A. J., KREUTTER, D. K. & BUTLER, P. C. (1996). Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proceedings of the National Academy of Sciences USA 93, 7283-7288.
110. JANUS, C., PEARSON, J., MCLAURIN, J., MATHEWS, P. M., JIANG, Y., SCHMIDT, S. D., CHISHTI, M. A., HORNE, P., HESLIN, D., FRENCH, J., MOUNT, H. T., NIXON, R. A., MERCKEN, M., BERGERON, C., FRASER, P. E., ST GEORGE-HYSLOP, P. & WESTAWAY, D. (2000). A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
111. JARRETT, J. T., BERGER, E. P. & LANSBURY JR., P. T. (1993). The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697.
112. JARRETT, J. T. & LANSBURY JR., P. T. (1993). Seeding 'one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058.
113. JOHNSTON, J. A., DALTON, M. J., GURNEY, M. E. & KOPITO, R. R. (2000). Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences USA 97, 12571-12576.
114. JOHNSTON, J. A., WARD, C. L. & KOPITO, R. R. (1998). Aggresomes: a cellular response to misfolded proteins. Journal of Cell Biology 143, 1883-1898.
115. JULIEN, J. P. (2001). Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell 104, 581-591.
116. JUNN, E., LEE, S. S., SUHR, U. T. & MOURADIAN, M. M. (2002). Parkin accumulation in aggresomes due to proteasome impairment. Journal of Biological Chemistry 277, 47870-47877.
117. KAD, N. M., MYERS, S. L., SMITH, D. P., SMITH, D. A., RADFORD, S. E. & THOMSON, N. H. (2003). Hierarchical assembly of beta2-microglobulin amyloid in vitro revealed by atomic force microscopy. Journal of Molecular Biology 330, 785-797.
118. KAGAN, B. L., HIRAKURA, Y., AZIMOV, R. & AZIMOVA, R. (2001). The channel hypothesis of Huntington's disease. Brain Research Bulletin 56, 281-284.
119. KAGAN, B. L., HIRAKURA, Y., AZIMOV, R., AZIMOVA, R. & LIN, M. C. (2002). The channel hypothesis of Alzheimer's disease: current status. Peptides 23, 1311-1315.
120. KAWAHARA, M., ARISPE, N., KURODA, Y. & ROJAS, E. (1997). Alzheimer's disease amyloid beta-protein forms Zn (2+)-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. Biophysical Journal 73, 67-75.
121. KAWAHARA, M. & KURODA, Y. (2000). Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis. Brain Research Bulletin 53, 389-397.
122. KAWAHARA, M. & KURODA, Y. (2001). Intracellular calcium changes in neuronal cells induced by Alzheimer's beta-amyloid protein are blocked by estradiol and cholesterol. Cellular and Molecular Neurobiology 21, 1-13.
123. KAWAHARA, M., KURODA, Y., ARISPE, N. & ROJAS, E. (2000). Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. Journal of Biological Chemistry 275, 14077-14083.
124. KAYED, R. & GLABE, C. G. (2004). Formation, stability and toxicity of annular protofibrils from different amyloid forming proteins. Neurobiology of Aging 25 (Suppl. 2), S144.
125. KAYED, R., HEAD, E., THOMPSON, J. L., MCINTIRE, T. M., MILTON, S. C., COTMAN, C. W. & GLABE, C. G. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
126. KAYED, R., SOKOLOV, Y., EDMONDS, B., MCINTIRE, T. M., MILTON, S. C., HALL, J. E. & GLABE, C. G. (2004). Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. Journal of Biological Chemistry 279, 46363-46366.
127. KAYLOR, J., BODNER, N., EDRIDGE, S., YAMIN, G., HONG, D. P. & FINK, A. L. (2005). Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein. Journal of Molecular Biology 353, 357-372.
128. KELLY, J. W. (1998). The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Current Opinion in Structural Biology 8, 101-106.
129. KHETERPAL, I., LASHUEL, H., HARTLEY, D., WALZ, T., LANSBURY JR., P. & WETZEL, R. (2003). Aβ proto.brils possess a stable core structure resistant to hydrogen exchange. Biochemistry 42, 14092-14098.
130. KIM, H. J., CHAE, S. C., LEE, D. K., CHROMY, B., LEE, S. C., PARK, Y. C., KLEIN, W. L., KRAFFT, G. A. & HONG, S. T. (2003). Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB Journal 17, 118-120.
131. KIRIK, D., ANNETT, L. E., BURGER, C., MUZYCZKA, N., MANDEL, R. J. & BJORKLUND, A. (2003). Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proceedings of the National Academy of Sciences USA 100, 2884-2889.
132. KIRIK, D., ROSENBLAD, C., BURGER, C., LUNDBERG, C., JOHANSEN, T. E., MUZYCZKA, N., MANDEL, R. J. & BJORKLUND, A. (2002). Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. Journal of Neuroscience 22, 2780-2791.
133. KITADA, T., ASAKAWA, S., HATTORI, N., MATSUMINE, H., YAMAMURA, Y., MINOSHIMA, S., YOKOCHI, M., MIZUNO, Y. & SHIMIZU, N. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608.
134. KLUG, G. M., LOSIC, D., SUBASINGHE, S. S., AGUILAR, M. I., MARTIN, L. L. & SMALL, D. H. (2003). Beta-amyloid protein oligomers induced by metal ions and acid pH are distinct from those generated by slow spontaneous ageing at neutral pH. European Journal of Biochemistry 270, 4282-4293.
135. KOPITO, R. R. (2000). Aggresomes, inclusion bodies and protein aggregation. Trends in Cell Biology 10, 524-530.
136. KOURIE, J. I. (2002). Prion channel proteins and their role in vacuolation and neurodegenerative diseases. European Biophysics Journal 31, 409-416.
137. KOURIE, J. I. & CULVERSON, A. (2000). Prion peptide fragment PrP[106-126] forms distinct cation channel types. Journal of Neuroscience Research 62, 120-133.
138. KOURIE, J. I., FARRELLY, P. V. & HENRY, C. L. (2001a). Channel activity of deamidated isoforms of prion protein fragment 106-126 in planar lipid bilayers. Journal of Neuroscience Research 66, 214-220.
139. KOURIE, J. I., HENRY, C. L. & FARRELLY, P. (2001b). Diversity of amyloid beta protein fragment [1-40]-formed channels. Cellular and Molecular Neurobiology 21, 255-284.
140. KOURIE, J. I., KENNA, B. L., TEW, D., JOBLING, M. F., CURTAIN, C. C., MASTERS, C. L., BARNHAM, K. J. & CAPPAI, R. (2003). Copper modulation of ion channels of PrP[106-126] mutant prion peptide fragments. Journal of Membrane Biology 193, 35-45.
141. KRUGER, R., KUHN, W., MULLER, T., WOITALLA, D., GRAEBER, M., KOSEL, S., PRZUNTEK, H., EPPLEN, J. T., SCHOLS, L. & RIESS, O. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature Genetics 18, 106-108.
142. KUEMMERLE, S., GUTEKUNST, C. A., KLEIN, A. M., LI, X. J., LI, S. H., BEAL, M. F., HERSCH, S.M. & FERRANTE, R. J. (1999). Huntington aggregates may not predict neuronal death in Huntington's disease. Annals of Neurology 46, 842-849.
143. KUO, Y. M., EMMERLING, M. R., VIGO-PELFREY, C., KASUNIC, T. C., KIRKPATRICK, J. B., MURDOCH, G. H., BALL, M. J. & ROHER, A. E. (1996). Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. Journal of Biological Chemistry 271, 4077-4081.
144. LAMBERT, M. P., BARLOW, A. K., CHROMY, B. A., EDWARDS, C., FREED, R., LIOSATOS, M., MORGAN, T. E., ROZOVSKY, I., TROMMER, B., VIOLA, K. L., WALS, P., ZHANG, C., FINCH, C. E., KRAFFT, G. A. & KLEIN, W. L. (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences USA 95, 6448-6453.
145. LAMBERT, M. P., VIOLA, K. L., CHROMY, B. A., CHANG, L., MORGAN, T. E., YU, J., VENTON, D. L., KRAFFT, G. A., FINCH, C. E. & KLEIN, W. L. (2001). Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. Journal of Neurochemistry 79, 595-605.
146. LANSBURY JR., P. T. & BRICE, A. (2002). Genetics of Parkinson's disease and biochemical studies of implicated gene products. Current Opinion in Genetics & Development 12, 299-306.
147. LASHUEL, H., HARTLEY, D., PETRE, B., WALL, J., SIMON, M., WALZ, T. & LANSBURY, P. (2003). Mixtures of wild-type and 'Arctic' Abeta40 in vitro accumulate protofibrils, including amyloid pores. Journal of Molecular Biology 332, 795-808.
148. LASHUEL, H., PETRE, B., WALL, J., SIMON, M., NOWAK, R., WALZ, T. & LANSBURY, P. (2002a). alpha-Synuclein, Especially the Parkinson's Disease-associated Mutants, Forms Pore-like Annular and Tubular Protofibrils. Journal of Molecular Biology 322, 1089.
149. LASHUEL, H. A., HARTLEY, D., PETRE, B. M., WALZ, T. & LANSBURY JR., P. T. (2002b). Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291.
150. LASHUEL, H. A., LAI, Z. & KELLY, J. W. (1998). Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry 37, 17851-17864.
151. LASHUEL, H. A., WURTH, C., WOO, L. & KELLY, J. W. (1999). The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 38, 13560-13573.
152. LEE, H. J., KHOSHAGHIDEH, F., PATEL, S. & LEE, S. J. (2004). Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. Journal of Neuroscience 24, 1888-1896.
153. LEE, H. J. & LEE, S. J. (2002). Characterization of cytoplasmic alpha-synuclein aggregates: Fibril formation is tightly linked to the inclusion forming process in cells. Journal of Biological Chemistry 277, 48976-48983.
154. LEE, H. J., SHIN, S. Y., CHOI, C., LEE, Y. H. & LEE, S. J. (2002). Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. Journal of Biological Chemistry 277, 5411-5417.
155. LEE, S. & EISENBERG, D. (2003). Seeded conversion of recombinant prion protein to a disulfide-bonded oligomer by a reduction-oxidation process. Nature Structural Biology 10, 725-730.
156. LEHMANN, S. & HARRIS, D. A. (1996). Mutant and infectious prion proteins display common biochemical properties in cultured cells. Journal of Biological Chemistry 271, 1633-1637.
157. LEMERE, C. A., BLUSZTAJN, J. K., YAMAGUCHI, H., WISNIEWSKI, T., SAIDO, T. C. & SELKOE, D. J. (1996). Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiology of Disease Journal 3, 16-32.
158. LEROY, E., BOYER, R., AUBURGER, G., LEUBE, B., ULM, G., MEZEY, E., HARTA, G., BROWNSTEIN, M. J., JONNALAGADA, S., CHERNOVA, T., DEHEJIA, A., LAVEDAN, C., GASSER, T., STEINBACH, P. J., WILKINSON, K. D. & POLYMEROPOULOS, M. H. (1998). The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452.
159. LI, J., UVERSKY, V. N. & FINK, A. L. (2001). Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40, 11604-11613.
160. LI, J., ZHU, M., MANNING-BOG, A. B., DI MONTE, D. A. & FINK, A. L. (2004). Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB Journal 18, 962-964.
161. LIN, H., BHATIA, R. & LAL, R. (2001). Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB Journal 15, 2433-2444.
162. 2+-sensitive channel in reconstituted lipid vesicles. Biochemistry 38, 11189-11196.
163. LIN, M. C. & KAGAN, B. L. (2002). Electrophysiologic properties of channels induced by Abeta25-35 in planar lipid bilayers. Peptides 23, 1215-1228.
164. LIN, M. C., MIRZABEKOV, T. & KAGAN, B. L. (1997). Channel formation by a neurotoxic prion protein fragment. Journal of Biological Chemistry 272, 44-47.
165. LINDBERG, M. J., TIBELL, L. & OLIVEBERG, M. (2002). Common denominator of Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis: decreased stability of the apo state. Proceedings of the National Academy of Sciences USA 99, 16607-16612.
166. LINDERSSON, E., BEEDHOLM, R., HOJRUP, P., MOOS, T., GAI, W., HENDIL, K. B. & JENSEN, P. H. (2004). Proteasomal inhibition by α-synuclein filaments and oligomers. Journal of Biological Chemistry 279, 12924-12934.
167. LO BIANCO, C., RIDET, J. L., SCHNEIDER, B. L., DEGLON, N. & AEBISCHER, P. (2002). alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proceedings of the National Academy of Sciences USA 99, 10813-10818.
168. LOTHARIUS, J. & BRUNDIN, P. (2002). Pathogenesis of Parkinson's disease: dopamine, vesicles and alphasynuclein. Nature Reviews Neuroscience 3, 932-942.
169. LOWE, R., POUNTNEY, D. L., JENSEN, P. H., GAI, W. P. & VOELCKER, N. H. (2004). Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Science 13, 3245-3252.
170. LU, B. Y. & CHANG, J. Y. (2002). Isolation and characterization of a polymerized prion protein. Biochemical Journal 364, 81-87.
171. LUE, L. F., KUO, Y. M., ROHER, A. E., BRACHOVA, L., SHEN, Y., SUE, L., BEACH, T., KURTH, J. H., RYDEL, R. E. & ROGERS, J. (1999). Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. American Journal of Pathology 155, 853-862.
172. MA, J. & LINDQUIST, S. (2002). Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science 298, 1785-1788.
173. MA, J., WOLLMANN, R. & LINDQUIST, S. (2002). Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298, 1781-1785.
174. MAAT-SCHIEMAN, M. L., VAN DUINEN, S. G., HAAN, J. & ROOS, R. A. (1992). Morphology of cerebral plaque-like lesions in hereditary cerebral hemorrhage with amyloidosis [in Dutch]. Acta Neuropathologica (Berlin) 84, 674-679.
175. MALISAUSKAS, M., ZAMOTIN, V., JASS, J., NOPPE, W., DOBSON, C. M. & MOROZOVA-ROCHE, L. A. (2003). Amyloid protofilaments from the calcium-binding protein equine lysozyme: formation of ring and linear structures depends on pH and metal ion concentration. Journal of Molecular Biology 330, 879-890.
176. MASLIAH, E. & HASHIMOTO, M. (2002). Development of new treatments for Parkinson's disease in transgenic animal models: a role for beta-synuclein. Neurotoxicology 23, 461-468.
177. MASLIAH, E., ROCKENSTEIN, E., VEINBERGS, I., MALLORY, M., HASHIMOTO, M., TAKEDA, A., SAGARA, Y., SISK, A. & MUCKE, L. (2000). Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269.
178. MCCLELLAN, A. J., TAM, S., KAGANOVICH, D. & FRYDMAN, J. (2005). Protein quality control: chaperones culling corrupt conformations. Nature Cell Biology 7, 736-741.
179. MCLEAN, C. A., CHERNY, R. A., FRASER, F. W., FULLER, S. J., SMITH, M. J., BEYREUTHER, K., BUSH, A. I. & MASTERS, C. L. (1999). Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Annals of Neurology 46, 860-866.
180. MCNAUGHT, K. S., MYTILINEOU, C., JNOBAPTISTE, R., YABUT, J., SHASHIDHARAN, P., JENNERT, P. & OLANOW, C. W. (2002). Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. Journal of Neurochemistry 81, 301-306.
181. MENESTRINA, G., SERRA, M. D. & PREVOST, G. (2001). Mode of action of beta-barrel pore-forming toxins of the staphylococcal alpha-hemolysin family. Toxicon 39, 1661-1672.
182. MENZIES, F. M., INCE, P. G. & SHAW, P. J. (2002). Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochemistry International 40, 543-551.
183. MIRZABEKOV, T. A., LIN, M. C. & KAGAN, B. L. (1996). Pore formation by the cytotoxic islet amyloid peptide amylin. Journal of Biological Chemistry 271, 1988-1992.
184. MOECHARS, D., DEWACHTER, I., LORENT, K., REVERSE, D., BAEKELANDT, V., NAIDU, A., TESSEUR, I., SPITTAELS, K., HAUTE, C. V., CHECLER, F., GODAUX, E., CORDELL, B. & VAN LEUVEN, F. (1999). Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. Journal of Biological Chemistry 274, 6483-6492.
185. MONOI, H. (1995). New tubular single-stranded helix of poly-L-amino acids suggested by molecular mechanics calculations: I. Homopolypeptides in isolated environments. Biophysical Journal 69, 1130-1141.
186. MONOI, H., FUTAKI, S., KUGIMIYA, S., MINAKATA, H. & YOSHIHARA, K. (2000). Poly-L-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. Biophysical Journal 78, 2892-2899.
187. MOORE, R. C., LEE, I. Y., SILVERMAN, G. L., HARRISON, P. M., STROME, R., HEINRICH, C., KARUNARATNE, A., PASTERNAK, S. H., CHISHTI, M. A., LIANG, Y., MASTRANGELO, P., WANG, K., SMIT, A. F., KATAMINE, S., CARLSON, G. A., COHEN, F. E., PRUSINER, S. B., MELTON, D. W., TREMBLAY, P., HOOD, L. E. & WESTAWAY, D. (1999). Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. Journal of Molecular Biology 292, 797-817.
188. MORGAN, D., DIAMOND, D. M., GOTTSCHALL, P. E., UGEN, K. E., DICKEY, C., HARDY, J., DUFF, K., JANTZEN, P., DICARLO, G., WILCOCK, D., CONNOR, K., HATCHER, J., HOPE, C., GORDON, M. & ARENDASH, G. W. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
189. MORISHIMA-KAWASHIMA, M. & IHARA, Y. (1998). The presence of amyloid beta-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry 37, 15247-15253.
190. MUCHOWSKI, P. J. (2002). Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron 35, 9-12.
191. MUCKE, L., MASLIAH, E., YU, G. Q., MALLORY, M., ROCKENSTEIN, E. M., TATSUNO, G., HU, K., KHOLODENKO, D., JOHNSON-WOOD, K. & MCCONLOGUE, L. (2000). High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. Journal of Neuroscience 20, 4050-4058.
192. NAKANO, R., INUZUKA, T., KIKUGAWA, K., TAKAHASHI, H., SAKIMURA, K., FUJII, J., TANIGUCHI, N. & TSUJI, S. (1996). Instability of mutant Cu/Zn superoxide dismutase (Ala4Thr) associated with familial amyotrophic lateral sclerosis. Neuroscience Letters 211, 129-131.
193. NASLUND, J., HAROUTUNIAN, V., MOHS, R., DAVIS, K. L., DAVIES, P., GREENGARD, P. & BUXBAUM, J. D. (2000). Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. Journal of the American Medical Association 283, 1571-1577.
194. NILSBERTH, C., WESTLIND-DANIELSSON, A., ECKMAN, C. B., CONDRON, M. M., AXELMAN, K., FORSELL, C., STENH, C., LUTHMAN, J., TEPLOW, D. B., YOUNKIN, S. G., NASLUND, J. & LANNFELT, L. (2001). The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nature Neuroscience 4, 887-893.
195. O'BRIEN, T. D., BUTLER, A. E., ROCHE, P. C., JOHNSON, K. H. & BUTLER, P. C. (1994). Islet amyloid polypeptide in human insulinomas. Evidence for intracellular amyloidogenesis. Diabetes 43, 329-336.
196. O'NUALLAIN, B. & WETZEL, R. (2002). Conformational Abs recognizing a generic amyloid fibril epitope. Proceedings of the National Academy of Sciences USA 99, 1485-1490.
197. OLOFSSON, A., HEBERT, H. & THELESTAM, M. (1993). The projection structure of perfringolysin O (Clostridium perfringens theta-toxin). FEBS Letters 319, 125-127.
198. ORLOVA, E. V., RAHMAN, M. A., GOWEN, B., VOLYNSKI, K. E., ASHTON, A. C., MANSER, C., VAN HEEL, M. & USHKARYOV, Y. A. (2000). Structure of alpha-latrotoxin oligomers reveals that divalent cation-dependent tetramers form membrane pores. Nature Structural Biology 7, 48-53.
199. PANDEY, N., SCHMIDT, R. E. & GALVIN, J. E. (2006). The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Experimental Neurology 197, 515-520.
200. PANOV, A. V., GUTEKUNST, C. A., LEAVITT, B. R., HAYDEN, M. R., BURKE, J. R., STRITTMATTER, W. J. & GREENAMYRE, J. T. (2002). Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neuroscience 5, 731-736.
201. PARBHU, A., LIN, H., THIMM, J. & LAL, R. (2002). Imaging real-time aggregation of amyloid beta protein (1-42) by atomic force microscopy. Peptides 23, 1265-1270.
202. PARK, J. Y. & LANSBURY JR., P. T. (2003). Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry 42, 3696-3700.
203. PILLOT, T., DROUET, B., PINCON-RAYMOND, M., VANDEKERCKHOVE, J., ROSSENEU, M. & CHAMBAZ, J. (2000). A nonfibrillar form of the fusogenic prion protein fragment [118-135] induces apoptotic cell death in rat cortical neurons. Journal of Neurochemistry 75, 2298-2308.
204. PILLOT, T., LINS, L., GOETHALS, M., VANLOO, B., BAERT, J., VANDEKERCKHOVE, J., ROSSENEU, M. & BRASSEUR, R. (1997). The 118-135 peptide of the human prion protein forms amyloid fibrils and induces liposome fusion. Journal of Molecular Biology 274, 381-393.
205. PITSCHKE, M., PRIOR, R., HAUPT, M. & RIESNER, D. (1998). Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nature Medicine 4, 832-834.
206. PODLISNY, M. B.,OSTASZEWSKI, B. L., SQUAZZO, S. L., KOO, E. H., RYDELL, R. E., TEPLOW, D.B. & SELKOE, D. J. (1995). Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. Journal of Biological Chemistry 270, 9564-9570.
207. POIRIER, M. A., LI, H., MACOSKO, J., CAI, S., AMZEL, M. & ROSS, C. A. (2002). Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. Journal of Biological Chemistry 277, 41032-41037.
208. POLLANEN, M. S., DICKSON, D. W. & BERGERON, C. (1993). Pathology and biology of the Lewy body. Journal of Neuropathology & Experimental Neurology 52, 183-191.
209. POLYMEROPOULOS, M. H., LAVEDAN, C., LEROY, E., IDE, S. E., DEHEJIA, A., DUTRA, A., PIKE, B., ROOT, H., RUBENSTEIN, J., BOYER, R., STENROOS, E. S., CHANDRASEKHARAPPA, S., ATHANASSIADOU, A., PAPAPETROPOULOS, T., JOHNSON, W. G., LAZZARINI, A. M., DUVOISIN, R. C., DI IORIO, G., GOLBE, L. I. & NUSSBAUM, R. L. (1997). Mutation in the alphasynuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
210. PORAT, Y., KOLUSHEVA, S., JELINEK, R. & GAZIT, E. (2003). The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 42, 10971-10977.
211. POUNTNEY, D. L., LOWE, R., QUILTY, M., VICKERS, J. C., VOELCKER, N. H. & GAI, W. P. (2004). Annular alpha-synuclein species from purified multiple system atrophy inclusions. Journal of Neurochemistry 90, 502-512.
212. QUIST, A., DOUDEVSKI, I., LIN, H., AZIMOVA, R., NG, D., FRANGIONE, B., KAGAN, B., GHISO, J. & LAL, R. (2005). Amyloid ion channels: a common structural link for protein-misfolding disease. Proceedings of the National Academy of Sciences USA 102, 10427-10432.
213. RAJAN, R. S., ILLING, M. E., BENCE, N. F. & KOPITO, R. R. (2001). Specificity in intracellular protein aggregation and inclusion body formation. Proceedings of the National Academy of Sciences USA 98, 13060-13065.
214. RAKHIT, R., CROW, J. P., LEPOCK, J. R., KONDEJEWSKI, L. H., CASHMAN, N.R. & CHAKRABARTTY, A. (2004). Monomeric Cu/Zn superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial ALS. Journal of Biological Chemistry 279, 15499-15504.
215. RAKHIT, R., CUNNINGHAM, P., FURTOS-MATEI, A., DAHAN, S., QI, X. F., CROW, J. P., CASHMAN, N. R., KONDEJEWSKI, L. H. & CHAKRABARTTY, A. (2002). Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. Journal of Biological Chemistry 277, 47551-47556.
216. RAY, S. S., NOWAK, R. J., STROKOVICH, K., BROWN JR., R. H, WALZ, T. & LANSBURY JR., P. T. (2004). An inter-subunit disulfide bond prevents in vitro aggregation of a superoxide dismutase-1 mutant linked to familial amytrophic lateral sclerosis. Biochemistry 43, 4899-4905.
217. REIXACH, N., DEECHONGKIT, S., JIANG, X., KELLY, J. W. & BUXBAUM, J. N. (2004). Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proceedings of the National Academy of Sciences USA 101, 2817-2822.
218. 2+-sensitive channel. Journal of Biological Chemistry 273, 13379-13382.
219. RHOADES, E. & GAFNI, A. (2003). Micelle formation by a fragment of human islet amyloid polypeptide. Biophysical Journal 84, 3480-3487.
220. RIESNER, D., KELLINGS, K., POST, K., WILLE, H., SERBAN, H., GROTH, D., BALDWIN, M. A. & PRUSINER, S. B. (1996). Disruption of prion rods generates 10-nm spherical particles having high alpha-helical content and lacking scrapie infectivity. Journal of Virology 70, 1714-1722.
221. ROCHET, J. C., CONWAY, K. A. & LANSBURY JR., P. T. (2000). Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry 39, 10619-10626.
222. ROCHET, J. C. & LANSBURY JR., P. T. (2000). Amyloid fibrillogenesis: themes and variations. Current Opinion in Structural Biology 10, 60-68.
223. ROCKENSTEIN, E., HANSEN, L. A., MALLORY, M., TROJANOWSKI, J. Q., GALASKO, D. & MASLIAH, E. (2001). Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Research 914, 48-56.
224. RODRIGUEZ, J. A., VALENTINE, J. S., EGGERS, D. K., ROE, J. A., TIWARI, A., BROWN JR., R. H. & HAYWARD, L. J. (2002). Familial amyotrophic lateral sclerosis-associated mutations decrease the thermal stability of distinctly metallated species of human copper/zinc superoxide dismutase. Journal of Biological Chemistry 277, 15932-15937.
225. ROHER, A. E., CHANEY, M. O., KUO, Y. M., WEBSTER, S. D., STINE, W. B., HAVERKAMP, L. J., WOODS, A. S., COTTER, R. J., TUOHY, J. M., KRAFFT, G. A., BONNELL, B. S. & EMMERLING, M. R. (1996). Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. Journal of Biological Chemistry 271, 20631-20635.
226. ROSEN, A. D. (1978). Amyotrophic lateral sclerosis. Clinical features and prognosis. Archives of Neurology 35, 638-642.
227. ROSEN, D. R., SIDDIQUE, T., PATTERSON, D., FIGLEWICZ, D. A., SAPP, P., HENTATI, A., DONALDSON, D., GOTO, J., O'REGAN, J. P., DENG, H. X., et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62.
228. ROSS, C. A. & PICKART, C. M. (2004). The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends in Cell Biology 14, 703-711.
229. ROSSI, D., COZZIO, A., FLECHSIG, E., KLEIN, M. A., RULICKE, T., AGUZZI, A. & WEISSMANN, C. (2001). Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain. EMBO Journal 20, 694-702.
230. RUBENSTEIN, R., MERZ, P. A., KASCSAK, R. J., CARP, R. I., SCALICI, C. L., FAMA, C. L. & WISNIEWSKI, H. M. (1987). Detection of scrapie-associated fibrils (SAF) and SAF proteins from scrapie-affected sheep. Journal of Infectious Diseases 156, 36-42.
231. SANDERSON, K. L., BUTLER, L. & INGRAM, V. M. (1997). Aggregates of a beta-amyloid peptide are required to induce calcium currents in neuron-like human teratocarcinoma cells: relation to Alzheimer's disease. Brain Research 744, 7-14.
232. SANGHERA, N. & PINHEIRO, T. J. (2002). Binding of prion protein to lipid membranes and implications for prion conversion. Journal of Molecular Biology 315, 1241-1256.
233. SCHERZINGER, E., SITTLER, A., SCHWEIGER, K., HEISER, V., LURZ, R., HASENBANK, R., BATES, G. P., LEHRACH, H. & WANKER, E. E. (1999). Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proceedings of the National Academy of Sciences USA 96, 4604-4609.
234. SCHUBERT, U., ANTON, L. C., GIBBS, J., NORBURY, C. C., YEWDELL, J. W. & BENNINK, J. R. (2000). Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404, 770-774.
235. SEKIYA, K., SATOH, R., DANBARA, H. & FUTAESAKU, Y. (1993). A ring-shaped structure with a crown formed by streptolysin O on the erythrocyte membrane. Journal of Bacteriology 175, 5953-5961.
236. SELKOE, D. J. (1994). Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annual Reviews of Cell Biology 10, 373-403.
237. SELLMAN, B. R., KAGAN, B. L. & TWETEN, R. K. (1997). Generation of a membrane-bound, oligomerized prepore complex is necessary for pore formation by Clostridium septicum alpha toxin. Molecular Microbiology 23, 551-558.
238. SERPELL, L. C., SUNDE, M., BENSON, M. D., TENNENT, G. A., PEPYS, M. B. & FRASER, P. E. (2000). The proto filament substructure of amyloid fibrils. Journal of Molecular Biology 300, 1033-1039.
239. SHARON, R., BAR-JOSEPH, I., FROSCH, M. P., WALSH, D. M., HAMILTON, J. A. & SELKOE, D. J. (2003a). The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583-595.
240. SHARON, R., BAR-JOSEPH, I., MIRICK, G. E., SERHAN, C.N. & SELKOE, D. J. (2003b). Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. Journal of Biological Chemistry 278, 49874-49881.
241. SHARON, R., GOLDBERG, M. S., BAR-JOSEF, I., BETENSKY, R. A., SHEN, J. & SELKOE, D. J. (2001). alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proceedings of the National Academy of Sciences USA 98, 9110-9115.
242. SHARPE, J. C. & LONDON, E. (1999). Diphtheria toxin forms pores of different sizes depending on its concentration in membranes: probable relationship to oligomerization. Journal of Membrane Biology 171, 209-221.
243. SHIBATA, N., HIRANO, A., KOBAYASHI, M., SIDDIQUE, T., DENG, H. X., HUNG, W. Y., KATO, T. & ASAYAMA, K. (1996). Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement. Journal of Neuropathology & Experimental Neurology 55, 481-490.
244. SHIMURA, H., SCHLOSSMACHER, M. G., HATTORI, N., FROSCH, M. P., TROCKENBACHER, A., SCHNEIDER, R., MIZUNO, Y., KOSIK, K. S. & SELKOE, D. J. (2001). Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269.
245. SHTILERMAN, M. D., DING, T. T. & LANSBURY JR., P. T. (2002). Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry 41, 3855-3860.
246. SHULTS, C. W. (2006). Lewy bodies. Proceedings of the National Academy of Sciences USA 103, 1661-1668.
247. SILVEIRA, J. R., RAYMOND, G. J., HUGHSON, A. G., RACE, R. E., SIM, V. L., HAYES, S. F. & CAUGHEY, B. (2005). The most infectious prion protein particles. Nature 437, 257-261.
248. SINGER, S. J. & DEWJI, N. N. (2006). Evidence that Perutz's double-beta-stranded subunit structure for beta-amyloids also applies to their channel-forming structures in membranes. Proceedings of the National Academy of Sciences USA 103, 1546-1550.
249. SINGLETON, A., MYERS, A. & HARDY, J. (2004). The law of mass action applied to neurodegenerative disease: a hypothesis concerning the aetiology and pathogenesis of complex diseases. Human Molecular Genetics 13, R123-R126.
250. SINGLETON, A. B., FARRER, M., JOHNSON, J., SINGLETON, A., HAGUE, S., KACHERGUS, J., HULIHAN, M., PEURALINNA, T., DUTRA, A., NUSSBAUM, R., LINCOLN, S., CRAWLEY, A., HANSON, M., MARAGANORE, D., ADLER, C., COOKSON, M. R., MUENTER, M., BAPTISTA, M., MILLER, D., BLANCATO, J., HARDY, J. & GWINN-HARDY, K. (2003). alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
251. SMITH, W. W., MARGOLIS, R. L., LI, X., TRONCOSO, J. C., LEE, M. K., DAWSON, V. L., DAWSON, T. M., IWATSUBO, T. & ROSS, C. A. (2005). Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. Journal of Neuroscience 25, 5544-5552.
252. SNYDER, H., MENSAH, K., THEISLER, C., LEE, J., MATOUSCHEK, A. & WOLOZIN, B. (2003). Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. Journal of Biological Chemistry 278, 11753-11759.
253. SOKOLOWSKI, F., MODLER, A. J., MASUCH, R., ZIRWER, D., BAIER, M., LUTSCH, G., MOSS, D. A., GAST, K. & NAUMANN, D. (2003). Formation of critical oligomers is a key event during conformational transition of recombinant syrian hamster prion protein. Journal of Biological Chemistry 278, 40481-40492.
254. SONG, L., HOBAUGH, M. R., SHUSTAK, C., CHELEY, S., BAYLEY, H. & GOUAUX, J. E. (1996). Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science 274, 1859-1866.
255. SOTI, C. & CSERMELY, P. (2002). Chaperones and aging: role in neurodegeneration and in other civilizational diseases. Neurochemistry International 41, 383-389.
256. SOUSA, M. M., CARDOSO, I., FERNANDES, R., GUIMARAES, A. & SARAIVA, M. J. (2001). Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. American Journal of Pathology 159, 1993-2000.
257. SOUSA, M. M., FERNANDES, R., PALHA, J. A., TABOADA, A., VIEIRA, P. & SARAIVA, M. J. (2002). Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. American Journal of Pathology 161, 1935-1948.
258. SPILLANTINI, M. G., CROWTHER, R. A., JAKES, R., CAIRNS, N. J., LANTOS, P. L. & GOEDERT, M. (1998a). Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience Letters 251, 205-208.
259. SPILLANTINI, M. G., CROWTHER, R. A., JAKES, R., HASEGAWA, M. & GOEDERT, M. (1998b). alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proceedings of the National Academy of Sciences USA 95, 6469-6473.
260. SRINIVASAN, R., JONES, E. M., LIU, K., GHISO, J., MARCHANT, R. E. & ZAGORSKI, M. G. (2003). pH-dependent amyloid and protofibril formation by the ABri peptide of familial British dementia. Journal of Molecular Biology 333, 1003-1023.
261. SRINIVASAN, R., MARCHANT, R. & ZAGORSKI, M. (2004). ABri peptide associated with familial British dementia forms pore-like protofibrillar structures. Amyloid 11, 10-13.
262. STEFANI, M. & DOBSON, C. M. (2003). Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. Journal of Molecular Medicine 81, 678-699.
263. STEGE, G. J., RENKAWEK, K., OVERKAMP, P. S., VERSCHUURE, P., VAN RIJK, A. F., REIJNEN-AALBERS, A., BOELENS, W. C., BOSMAN, G. J. & DE JONG, W.W. (1999). The molecular chaperone alphaB-crystallin enhances amyloid beta neurotoxicity. Biochemical and Biophysical Research Communications 262, 152-156.
264. STINE JR., W. B., DAHLGREN, K. N., KRAFFT, G. A. & LADU, M. J. (2003). In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. Journal of Biological Chemistry 278, 11612-11622.
265. SUNDE, M., SERPELL, L. C., BARTLAM, M., FRASER, P. E., PEPYS, M. B. & BLAKE, C. C. (1997). Common core structure of amyloid fibrils by synchrotron X-ray diffraction. Journal of Molecular Biology 273, 729-739.
266. SUPATTAPONE, S., BOSQUE, P., MURAMOTO, T., WILLE, H., AAGAARD, C., PERETZ, D., NGUYEN, H. O., HEINRICH, C., TORCHIA, M., SAFAR, J., COHEN, F. E., DEARMOND, S. J., PRUSINER, S. B. & SCOTT, M. (1999). Prion protein of 106 residues creates an artifical transmission barrier for prion replication in transgenic mice. Cell 96, 869-878.
267. TADJIBAEVA, G., SABIROV, R. & TOMITA, T. (2000). Flammutoxin, a cytolysin from the edible mushroom Flammulina velutipes, forms two different types of voltage-gated channels in lipid bilayer membranes. Biochimica et Biophysica Acta 1467, 431-443.
268. TANAKA, Y., ENGELENDER, S., IGARASHI, S., RAO, R. K., WANNER, T., TANZI, R. E., SAWA, A., DAWSON, V. L., DAWSON, T. M. & ROSS, C. A. (2001). Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Human Molecular Genetics 10, 919-926.
269. TAYLOR, J. P., TANAKA, F., ROBITSCHEK, J., SANDOVAL, C. M., TAYE, A., MARKOVIC-PLESE, S. & FISCHBECK, K. H. (2003). Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Human Molecular Genetics 12, 749-757.
270. TENG, M. H., YIN, J. Y., VIDAL, R., GHISO, J., KUMAR, A., RABENOU, R., SHAH, A., JACOBSON, D. R., TAGOE, C., GALLO, G. & BUXBAUM, J. (2001). Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Laboratory Investigation 81, 385-396.
271. TERRY, R. D., MASLIAH, E., SALMON, D. P., BUTTERS, N., DETERESA, R., HILL, R., HANSEN, L. A. & KATZMAN, R. (1991). Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Annals of Neurology 30, 572-580.
272. TIWARI, A. & HAYWARD, L. J. (2003). Familial amyotrophic lateral sclerosis mutants of copper/zinc superoxide dismutase are susceptible to disulfide reduction. Journal of Biological Chemistry 278, 5984-5992.
273. TOMPKINS, M. M. & HILL, W. D. (1997). Contribution of somal Lewy bodies to neuronal death. Brain Research 775, 24-29.
274. TOWNSEND, M., SHANKAR, G. M., MEHTA, T., WALSH, D. M. & SELKOE, D. J. (2006). Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. Journal of Physiology 572, 477-492.
275. TURNER, B. J., LOPES, E. C. & CHEEMA, S. S. (2003). Neuromuscular accumulation of mutant superoxide dismutase 1 aggregates in a transgenic mouse model of familial amyotrophic lateral sclerosis. Neuroscience Letters 350, 132-136.
276. URUSHITANI, M., KURISU, J., TSUKITA, K. & TAKAHASHI, R. (2002). Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. Journal of Neurochemistry 83, 1030-1042.
277. URYU, K., GIASSON, B. I., LONGHI, L., MARTINEZ, D., MURRAY, I., CONTE, V., NAKAMURA, M., SAATMAN, K., TALBOT, K., HORIGUCHI, T., MCINTOSH, T., LEE, V. M. & TROJANOWSKI, J. Q. (2003). Age-dependent synuclein pathology following traumatic brain injury in mice. Experimental Neurology 184, 214-224.
278. VALEVA, A., PALMER, M. & BHAKDI, S. (1997). Staphylococcal alpha-toxin: formation of the heptameric pore is partially cooperative and proceeds through multiple intermediate stages. Biochemistry 36, 13298-13304.
279. VENDRELY, C., VALADIE, H., BEDNAROVA, L., CARDIN, L., PASDELOUP, M., CAPPADORO, J., BEDNAR, J., RINAUDO, M. & JAMIN, M. (2005). Assembly of the full-length recombinant mouse prion protein I. Formation of soluble oligomers. Biochimica et Biophysica Acta 1724, 355-366.
280. VIDAL, R., FRANGIONE, B., ROSTAGNO, A., MEAD, S., REVESZ, T., PLANT, G. & GHISO, J. (1999). A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 399, 776-781.
281. VOLLES, M. J. & LANSBURY JR., P. T. (2002). Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595-4602.
282. VOLLES, M. J. & LANSBURY JR., P. T. (2003). Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42, 7871-7878.
283. VOLLES, M. J., LEE, S. J., ROCHET, J. C., SHTILERMAN, M. D., DING, T. T., KESSLER, J. C. & LANSBURY JR., P. T. (2001). Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819.
284. WACKER, J. L., ZAREIE, M. H., FONG, H., SARIKAYA, M. & MUCHOWSKI, P. J. (2004). Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nature Structural & Molecular Biology 11, 1215-1222.
285. WALKER, B., KRISHNASASTRY, M., ZORN, L. & BAYLEY, H. (1992). Assembly of the oligomeric membrane pore formed by Staphylococcal alpha-hemolysin examined by truncation mutagenesis. Journal of Biological Chemistry 267, 21782-21786.
286. WALLACE, A. J., STILLMAN, T. J., ATKINS, A., JAMIESON, S. J., BULLOUGH, P. A., GREEN, J. & ARTYMIUK, P. J. (2000). E. coli hemolysin E (HlyE, ClyA, SheA): X-ray crystal structure of the toxin and observation of membrane pores by electron microscopy. Cell 100, 265-276.
287. WALSH, D. M., HARTLEY, D. M., KUSUMOTO, Y., FEZOUI, Y., CONDRON, M. M., LOMAKIN, A., BENEDEK, G. B., SELKOE, D. J. & TEPLOW, D. B. (1999). Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. Journal of Biological Chemistry 274, 25945-25952.
288. WALSH, D. M., KLYUBIN, I., FADEEVA, J. V., CULLEN, W. K., ANWYL, R., WOLFE, M. S., ROWAN, M. J. & SELKOE, D. J. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
289. WALSH, D. M., LOMAKIN, A., BENEDEK, G. B., CONDRON, M. M. & TEPLOW, D. B. (1997). Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. Journal of Biological Chemistry 272, 22364-22372.
290. WALSH, D. M., TSENG, B. P., RYDEL, R. E., PODLISNY, M. B. & SELKOE, D. J. (2000). The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39, 10831-10839.
291. WANG, H. W., PASTERNAK, J. F., KUO, H., RISTIC, H., LAMBERT, M. P., CHROMY, B., VIOLA, K. L., KLEIN, W. L., STINE, W. B., KRAFFT, G. A. & TROMMER, B. L. (2002a). Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Research 924, 133-140.
292. WANG, L., LASHUEL, H. A., WALZ, T. & COLON, W. (2002b). Murine apolipoprotein serum amyloid A in solution forms a hexamer containing a central channel. Proceedings of the National Academy of Sciences USA 99, 15947-15952.
293. WANG, Q., WALSH, D. M., ROWAN, M. J., SELKOE, D. J. & ANWYL, R. (2004). Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. Journal of Neuroscience 24, 3370-3378.
294. WATANABE, M., DYKES-HOBERG, M., CULOTTA, V. C., PRICE, D. L., WONG, P. C. & ROTHSTEIN, J. D. (2001). Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiology of Disease Journal 8, 933-941.
295. WATASE, K., WEEBER, E. J., XU, B., ANTALFFY, B., YUVAPAYLOR, L., HASHIMOTO, K., KANO, M., ATKINSON, R., SUN, Y., ARMSTRONG, D. L., SWEATT, J. D., ORR, H. T., PAYLOR, R. & ZOGHBI, H. Y. (2002). A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34, 905-919.
296. WEINREB, P. H., ZHEN, W., POON, A. W., CONWAY, K. A. & LANSBURY JR., P. T. (1996). NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715.
297. WETZEL, R. (1994). Mutations and off-pathway aggregation of proteins. Trends in Biotechnology 12, 193-198.
298. WHALEN, B. M., SELKOE, D. J. & HARTLEY, D. M. (2005). Small non-fibrillar assemblies of amyloid beta-protein bearing the Arctic mutation induce rapid neuritic degeneration. Neurobiology of Disease Journal 20, 254-266.
299. WHITE, J. A., MANELLI, A. M., HOLMBERG, K. H., VAN ELDIK, L. J. & LADU, M. J. (2005). Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiology of Disease Journal 18, 459-465.
300. WOOD, W. G., SCHROEDER, F., IGBAVBOA, U., AVDULOV, N. A. & CHOCHINA, S. V. (2002). Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiology of Aging 23, 685-694.
301. XU, J., KAO, S. Y., LEE, F. J., SONG, W., JIN, L.W. & YANKNER, B. A. (2002). Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nature Medicine 8, 600-606.
302. YONG, W., LOMAKIN, A., KIRKITADZE, M. D., TEPLOW, D. B., CHEN, S. H. & BENEDEK, G. B. (2002). Structure determination of micelle-like intermediates in amyloid beta-protein fibril assembly by using small angle neutron scattering. Proceedings of the National Academy of Sciences USA 99, 150-154.
303. ZARRANZ, J. J., ALEGRE, J., GOMEZ-ESTEBAN, J. C., LEZCANO, E., ROS, R., AMPUERO, I., VIDAL, L., HOENICKA, J., RODRIGUEZ, O., ATARES, B., LLORENS, V., TORTOSA, E. G., DEL SER, T., MUNOZ, D. G. & DE YEBENES, J. G. (2004). The new mutation, E46K, of alpha-synuclein causes parkinson and Lewy body dementia. Annals of Neurology 55, 164-173.
304. ZHANG, Y., MCLAUGHLIN, R., GOODYER, C. & LEBLANC, A. (2002). Selective cytotoxicity of intracellular amyloid beta peptide 1-42 through p53 and Bax in cultured primary human neurons. Journal of Cell Biology 156, 519-529.
305. ZHU, M. & FINK, A. L. (2003). Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, Program No. 132.12.
306. ZHU, M., RAJMANI, S., KAYLOR, J., HAN, S., ZHOU, F. & FINK, A. L. (2004). The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. Journal of Biological Chemistry 279, 26846-26857.
307. ZITZER, A., WALEV, I., PALMER, M. & BHAKDI, S. (1995). Characterization of Vibrio cholerae El Tor cytolysin as an oligomerizing pore-forming toxin. Medical Microbiology and Immunology (Berlin) 184, 37-44.
308. ZOGHBI, H. Y. & ORR, H. T. (2000). Glutamine repeats and neurodegeneration. Annual Review of Neuroscience 23, 217-247.